Dr. Perrine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 Washingotn St
Boston, MA 02118Phone+1 617-636-5355- Is this information wrong?
Summary
- Dr. Susan Perrine is a pediatric hematologist/oncologist in Boston, MA and is affiliated with Boston University School of Medicine, Phoenicia BioSciences, and Tufts Medical Center. She obtained her MD and Pediatric residency at Tufts University School of Medicine, Fellowship at Children's Hospital Boston, SM from Harvard School of Public Health. She specializes in hemoglobinopathies and thalassemia, pediatric anemia, red cell hematology, clinical drug development and clinical trials. She directed an NIH-funded Translational Medicine laboratory program for 30 yrs, and new drug development in academia and biotech, as CSO, CMO, bringing 5 new INDs into clinical trials.
She is interested in expanding medical care services to underserved populations, building Transition Programs and Medical Homes, and increasing utilization of new therapies in hemoglobinopathy patients who are not receiving regular care.
Clinical Expertise
- Pediatric hematology / oncology, Hematologic oncology, Pediatrics, Clinical trials, drug development
Education & Training
Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1979 - 1980
Tufts Medical CenterResidency, Pediatrics, 1976 - 1979
Harvard School of Public HealthSM, 1976 - 1978
Tufts University School of MedicineClass of 1976
Certifications & Licensure
DC State Medical License 2014 - 2024
MA State Medical License 1978 - 2024
CA State Medical License 1982 - 2021- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Harrington Scholar Innovator Award Harrington Disocvery Institute, 2016-2018
Clinical Trials
- Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies Start of enrollment: 2008 Sep 01
- Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon Start of enrollment: 2012 May 01
- The BENeFiTS Trial in Beta Thalassemia Intermedia Start of enrollment: 2020 Oct 05
Roles: Contact, Study Director
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsNovel histone deacetylase inhibitor CT-101 induces γ-globin gene expression in sickle erythroid progenitors with targeted epigenetic effects.Louis H. Junker, Biaoru Li, Xingguo Zhu, Sivanagireddy Koti, Ryan E. Cerbone, Clifford L. Hendrick, Jose Sangerman, Susan P. Perrine, Betty S. Pace> ;Blood Cells, Molecules & Diseases. 2022 Mar 1
- 6 citationsBenserazide racemate and enantiomers induce fetal globin gene expression in vivo: Studies to guide clinical development for beta thalassemia and sickle cell diseaseBetty S. Pace, Susan P. Perrine, Biaoru Li, Levi Makala, Hongyan Xu, Mayuko Takezaki, Roman F. Wolf, Amy Wang, Xin Xu, Junfeng Huang, Asaf Alimardanov, Gregory J. Tawa...> ;Blood Cells, Molecules & Diseases. 2021 Mar 12
- 4 citationsAn oral HemokineTM, α-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivoDouglas V. Faller, Serguei A. Castaneda, Daohong Zhou, Merriline Vedamony, Peter E. Newburger, Gary L. White, Stanley D. Kosanke, P. Artur Plett, Christie M. Orschell,...> ;Blood Cells, Molecules & Diseases. 2017 Mar 1
- Join now to see all
Press Mentions
Petition to Save Boston’s Tufts Children’s Hospital Garners More Than 56,000 SignaturesFebruary 4th, 2022
Grant Support
- Development of a Clinical Hemoglobin ModulatorNIH2020–2023
- Novel HDAC Inhibitors for Treatment of HemoglobinopathiesNIH NHLBI2018–2019
- Virus Targeted Therapy for MalignancyNCI2017–2019
- Clinical Development of a Hemoglobin ModulatorNIH2014–2017
- Novel Globin Gene ModulatorsNIH NIDDK1998–2017
- Globin Gene Expression in Sickle Cell Genotype Specific iPS cellsNIH2011–2016
- Topical therapeutic to Promote Healing of Refractory WoundsNIH2013–2015
- Selective HDACC 1/2 Inhibitors for HemoglobinopathiesNIH NHLBI2013–2014
- Oral Agents to Stimulate Neutrophil ProductionNIH2010–2012
- Development of an Oncogene Targeted TherapeuticNCI2009–2011
Professional Memberships
- Member
Other Languages
- French
Hospital Affiliations
UCSF Benioff Children's Hospital OaklandOakland, California
Tufts Medical CenterBoston, Massachusetts
Industry Relationships
- President, Chief Medical Officer, Phoenicia BioSciences IncDirecting clinical trials in thalassemia and sickle cell disease, EBV lymphoma, sickle cell leg ulcers2008 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
